Back
Sarepta Therapeutics Vs. Apellis Pharmaceuticals Industry Stock Comparison
Sell
50
SRPT
Sarepta Therapeutics
Last Price:
131.39
Seasonality Move:
8.89%
Sell
34
APLS
Apellis Pharmaceuticals
Last Price:
41.30
Seasonality Move:
9.35%
Sell
50
Sarepta Therapeutics (SRPT)
is a Sell
Is Sarepta Therapeutics a Buy, Sell or Hold?
- The current Sarepta Therapeutics [SRPT] share price is $132.74. The Score for SRPT is 50, which is 0% below its historic median score of 50, and infers higher risk than normal.
- SRPT is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
34
Apellis Pharmaceuticals (APLS)
is a Sell
Is Apellis Pharmaceuticals a Buy, Sell or Hold?
- The current Apellis Pharmaceuticals [APLS] share price is $42.00. The Score for APLS is 34, which is 32% below its historic median score of 50, and infers higher risk than normal.
- APLS is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
SRPT Stock Price Chart
What is Sarepta Therapeutics's stock price today?
-
The Sarepta Therapeutics share price today is $132.74
The current trend is moderately bullish and SRPT is experiencing buying pressure, which is a positive indicator for future bullish movement.
APLS Stock Price Chart
What is Apellis Pharmaceuticals's stock price today?
-
The Apellis Pharmaceuticals share price today is $42.00
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and APLS is experiencing buying pressure, which is a positive indicator for future bullish movement.
SRPT Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 2.32 | Buy |
| Relative Strength Index (14 RSI): | 60.57 | Buy |
| Chaikin Money Flow: | 825203 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (120.05 - 133.59) | Buy |
| Bollinger Bands (100): | (112.21 - 133.05) | Buy |
APLS Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -3.06 | Sell |
| Relative Strength Index (14 RSI): | 35.58 | Sell |
| Chaikin Money Flow: | 2689175 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (43.21 - 49.83) | Sell |
| Bollinger Bands (100): | (50.32 - 66.9) | Sell |
SRPT Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 132.8 | Sell |
| 20-day SMA: | 128.89 | Buy |
| 50-day SMA: | 126.17 | Buy |
| 200-day SMA: | 113.39 | Buy |
| 8-day EMA: | 132.23 | Buy |
| 20-day EMA: | 130 | Buy |
| 50-day EMA: | 126.73 | Buy |
| 200-day EMA: | 118.1 | Buy |
APLS Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 42.36 | Sell |
| 20-day SMA: | 45.62 | Sell |
| 50-day SMA: | 51.91 | Sell |
| 200-day SMA: | 51.66 | Sell |
| 8-day EMA: | 42.89 | Sell |
| 20-day EMA: | 45.6 | Sell |
| 50-day EMA: | 50.77 | Sell |
| 200-day EMA: | 55.72 | Sell |
Sarepta Therapeutics Earnings Growth & SRPT Earnings Dates
- Analysts estimate an earnings increase this quarter of $2.06 per share, an increase next quarter of $1.31 per share, an increase this year of $6.16 per share, and an increase next year of $6.01 per share.
Apellis Pharmaceuticals Earnings Growth & APLS Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.88 per share, an increase next quarter of $0.34 per share, an increase this year of $3.60 per share, and an increase next year of $2.16 per share.
Sarepta Therapeutics Technical Analysis
| May 3 | May 6 | May 7 | May 8 | May 9 | May 10 | May 13 | May 14 | May 15 | May 16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| May | ||||||||||
| 03 | 06 | 07 | 08 | 09 | 10 | 13 | 14 | 15 | 16 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Apellis Pharmaceuticals Technical Analysis
| May 3 | May 6 | May 7 | May 8 | May 9 | May 10 | May 13 | May 14 | May 15 | May 16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| May | ||||||||||
| 03 | 06 | 07 | 08 | 09 | 10 | 13 | 14 | 15 | 16 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||